Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Safety of Effivia®, a Bevacizumab Biosimilar: Phase IV, Observational, Multicenter Clinical Study in Mexican Population

NCT06313268 is registered in ClinicalTrials.gov with Laboratorios Liomont as lead sponsor.

NCT NCT06313268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06313268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Safety of Effivia®, a Bevacizumab Biosimilar: Phase IV, Observational, Multicenter Clinical Study in Mexican Population
Lead sponsor
Laboratorios Liomont
Phase
Observational
Overall status
Completed
Start date
August 11, 2022
Completion date
September 2, 2024
Enrollment
83 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cervical cancer, metastatic colorectal cancer, non squamous non small cell lung cancer